Navigation Links
Epizyme, Inc. Reports Second Quarter 2013 Financial Results
Date:7/31/2013

Net loss was $2.2 million for the second quarter of 2013 and $9.7 million for the six months ended June 30, 2013, compared to net income of $4.9 million and net loss of $0.6 million for the comparable periods in 2012. The 2012 second quarter net income was largely driven by the revenue recognition of a portion of the $68.0 million upfront payment received from Celgene in April 2012.
  • End of Year Cash Guidance Epizyme expects that its cash and cash equivalents will be approximately $115 million as of December 31, 2013, which it believes will fund the Company until at least mid-2015. Full-year 2013 net cash used in operating activities is expected to be approximately $65 million.
  • Upcoming Milestones

  • EPZ-5676 In the second half of 2013, Epizyme plans to complete the dose escalation stage of the Phase 1 study and initiate the expansion cohort, which will be limited to patients with MLL-r and which may provide an initial assessment of therapeutic effect.
  • EPZ-6438 In 2014, Epizyme plans to initiate the Phase 2 portion of the Phase 1/2 study of EPZ-6438, which will be limited to patients with point mutations in EZH2 and which may provide an initial assessment of therapeutic effect.
  • Conference Call InformationEpizyme will host a conference call and live audio webcast today at 4:30 p.m. EDT to discuss the quarter and provide a corporate update. To participate in the conference call, please dial 1-877-844-6886 (domestic) or 1-970-315-0315 (international) and refer to conference ID 17477005. The live webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.epizyme.com

    The archived webcast will be available on the Company's website beginning approximately two hours after the event.

    About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients w
    '/>"/>

    SOURCE Epizyme, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. China Medical Flat Panel Detector Market & Pressure Injector 2013 Research Reports Now Available at ReportsnReports.com
    2. Global Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline: MarketResearchReports.Biz
    3. Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope
    4. China Radiotherapy Simulator Market & Digital Radiography 2013 Research Reports Now Available at ReportsnReports.com
    5. Neurocrine Biosciences Reports Second Quarter 2013 Results
    6. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
    7. Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2013
    8. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
    9. Cepheid Reports 2013 Second Quarter Results
    10. Quest Diagnostics Reports Second Quarter 2013 Financial Results
    11. Global GIS Market in the Retail Industry to 2016: Industry Analysis, Growth, Strategy, Size, Shares, Trend and Forecast Research Report Available at MarketResearchReports
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/16/2014)... CIRTEC Medical Systems’ Board of Directors ... of CIRTEC. , “I am delighted to be ... noted Brian Highley. “The company has made great strides ... growth over the past two years. The goal now ... and expand the services Cirtec offers its medical device ...
    (Date:9/16/2014)... Ky. , Sept. 16, 2014  LABSCO, ... technologies and products to hospitals, physician office laboratories ... that, effective October 1, 2014, it will serve ... specified hospital market segments and as a semi-exclusive ... the 48 contiguous United States ...
    (Date:9/16/2014)... According to Jeff Howell, Partner of Nidea Corporate ... development in Downtown Toronto is expanding at a blistering ... storeys of new development last week (including three new ... the Toronto skyline for the foreseeable future in a ... new development. , As the Toronto city council met ...
    (Date:9/15/2014)... 15, 2014 EnGeneIC, Ltd. , ... treatment of cancer through the targeted delivery of ... together with the Asbestos Disease Research Institute (ADRI), ... South Wales (NSW) Premier,s Award for Excellence in ... the hospitals that will be involved in the ...
    Breaking Biology Technology:LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3
    ... , BONITA SPRINGS, Fla., Nov. 18 ... the technology group The Linde Group have agreed ... to identify the optimum management of carbon dioxide (CO2) ... technology. This cooperation will see the companies join forces ...
    ... BALTIMORE, Nov. 18 Champions Biotechnology, Inc. ... with a predictive preclinical platform aimed at accelerating the ... established an exclusive licensing agreement with Yale University and ... cancer treatment. Scientists from Yale and Southern Research ...
    ... , BOTHELL, Wash., Nov. 18 BioLife Solutions, Inc. ... of proprietary cGMP hypothermic storage and cryopreservation media products for ... granted a Japanese patent for an application that includes claims ... cold temperatures used in biopreservation. The patent is titled " ...
    Cached Biology Technology:Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 2Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 2Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 4BioLife Solutions Granted Japanese Biopreservation Patent 2BioLife Solutions Granted Japanese Biopreservation Patent 3
    (Date:9/16/2014)... certain traits from our parents that are pre-determined. But ... out by taking certain drugs or better yet, just ... of researchers at the Boston University School of Medicine ... , Epigenetics regulates gene expression in a reversible ... prevent permanent mutations or alterations within the gene themselves. ...
    (Date:9/16/2014)... fall marks a new school year, a new football ... Space Station. In September, SpaceX,s Dragon spacecraft is scheduled ... and investigations as part of the company,s fourth contracted ... will be the third suite of research investigations sponsored ... Space (CASIS). With the role of managing the U.S. ...
    (Date:9/16/2014)... peacock show its extravagant, colorful tail feathers in courtship ... used a special camera developed by an engineer at ... northern swordtail fish choose their mates based on a ... Texas at Austin used a bioinspired polarization camera developed ... & engineering at Washington University, to make the discovery. ...
    Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3Camera developed at WUSTL sheds light on mate choice of swordtail fish 2
    ... 2009 A canine chromosome 7 locus that confers ... identified through a collaboration between the Behavior Service at ... Medical Genetics at the University of Massachusetts Medical School ... Technology. The findings are published in the January 2010 ...
    ... lll. Researchers report that Helicobacter pylori , ... environment of the human stomach, directly activates an enzyme ... types of cancer, including gastric cancer. Chronic infection ... factor for several forms of gastric cancer, but researchers ...
    ... scientific conference has provided new evidence for the ... of spectacular marine life, including deadly jellyfish, basking ... ,South West Marine Ecosystems, meeting, held in Plymouth ... the scientific, conservation, fishing and eco-tourism sectors. The ...
    Cached Biology News:Canine compulsive disorder gene identified in dogs 2Canine compulsive disorder gene identified in dogs 3Team finds link between stomach-cancer bug and cancer-promoting factor 2Team finds link between stomach-cancer bug and cancer-promoting factor 3Conference highlights impact of unsettled summer weather on UK marine life 2
    ... in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and ... royalties for your hard work and endeavour! ... build it up,and market it internationally. We ...
    Topoisomerase I...
    ...
    ... vaccinia virus is a type I eukaryotic ... superhelical turns (also called right- and left-handed ... of the reaction is a covalently closed, ... superhelical turns. DNA Topoisomerase I does not ...
    Biology Products: